<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2259">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131750</url>
  </required_header>
  <id_info>
    <org_study_id>RIR-PCI</org_study_id>
    <nct_id>NCT05131750</nct_id>
  </id_info>
  <brief_title>RIR and the Impact on Clinical Outcomes in Patients Undergoing PCI</brief_title>
  <official_title>A Prospective Study of Residual Inflammatory Risk and the Impact on Clinical Outcomes in Patients Undergoing Percutaneous Coronary Interventions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wuhan Union Hospital, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Coronary heart disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to&#xD;
      coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly&#xD;
      improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI),&#xD;
      these patients are still at high risk of major adverse cardiovascular events (MACE).&#xD;
&#xD;
      At present, the concept of residual inflammation risk (RIR) has aroused widespread concern.&#xD;
      RIR is an important independent risk in patients with CAD. Foreign studies indicate that&#xD;
      hsCRP ≥ 2mg / L is the definition standard of RIR in CAD. In China, there is no defined value&#xD;
      of RIR for patients undergoing PCI, and the incidence of RIR has not been investigated&#xD;
      clearly. At the same time, the impact of dynamic changes of hsCRP on MACE in PCI population&#xD;
      needs to be further explored. Therefore, in this study, we plan to recruit patients&#xD;
      undergoing PCI, and observe the impact of RIR by serial hsCRP measurements on the prognosis&#xD;
      of these patients followed up for 5 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Serial hsCRP measurements with ≥ 4 weeks between both measurements are defined in this&#xD;
      analysis. Time-to-event is measured from first hsCRP measurement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 6, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Major adverse cardiovascular events (MACEs)</measure>
    <time_frame>60 months</time_frame>
    <description>Time to occurrence of composite endpoint of all-cause death, nonfatal myocardial infarction or nonfatal stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events + (MACEs+)</measure>
    <time_frame>60 months</time_frame>
    <description>Time to occurrence of composite endpoints of all-cause death, nonfatal myocardial infarction, nonfatal stroke, revascularization due to ischemia, or hospitalization due to unstable angina pectoris</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>60 months</time_frame>
    <description>Time to occurrence of all-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>60 months</time_frame>
    <description>Time to occurrence of cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nonfatal myocardial infarction</measure>
    <time_frame>60 months</time_frame>
    <description>Time to occurrence of nonfatal myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to unstable angina pectoris</measure>
    <time_frame>60 months</time_frame>
    <description>Time to occurrence of hospitalization due to unstable angina pectoris</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Revascularization due to ischemia</measure>
    <time_frame>60 months</time_frame>
    <description>Time to occurrence of revascularization due to ischemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-stent thrombosis</measure>
    <time_frame>60 months</time_frame>
    <description>Time to occurrence of in-stent thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nonfatal stroke</measure>
    <time_frame>60 months</time_frame>
    <description>Time to occurrence of nonfatal stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>60 months</time_frame>
    <description>Time to occurrence of bleeding</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1408</enrollment>
  <condition>hsCRP</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with coronary heart disease completed all planned PCI during hospitalization&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants who understand and sign the informed consent form voluntarily;&#xD;
&#xD;
          2. Age ≥ 18 years old and ≤ 80 years old, regardless of sex;&#xD;
&#xD;
          3. The hospitalized patients with coronary heart disease undergoing PCI;&#xD;
&#xD;
          4. Complete all planned PCI during hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients do not receive standardized treatment according to guidelines after being&#xD;
             diagnosed with coronary heart disease;&#xD;
&#xD;
          2. Uncontrolled infectious diseases during the screening period;&#xD;
&#xD;
          3. In the screening stage, patients with immune diseases or immune-related diseases such&#xD;
             as systemic lupus erythematosus, asthma, inflammatory bowel disease, gout, malignant&#xD;
             tumor and so on;&#xD;
&#xD;
          4. Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and&#xD;
             chemotherapeutic drugs during the study period;&#xD;
&#xD;
          5. Surgical or interventional treatment was performed within 3 months before the&#xD;
             screening period;&#xD;
&#xD;
          6. Pregnant women, lactating women or women of childbearing age who do not use effective&#xD;
             contraceptives;&#xD;
&#xD;
          7. Participated in other clinical trials within 3 months before the screening period;&#xD;
&#xD;
          8. The researchers determined that other conditions in which the patient was not suitable&#xD;
             to participate in the clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Miao Yu, Doctor</last_name>
    <phone>+8613995562434</phone>
    <email>yumiaodavid@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Cheng, Doctor</last_name>
      <phone>+8602785726011</phone>
      <email>nathancx@hust.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiang Cheng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.</citation>
    <PMID>28845751</PMID>
  </results_reference>
  <results_reference>
    <citation>Kalkman DN, Aquino M, Claessen BE, Baber U, Guedeney P, Sorrentino S, Vogel B, de Winter RJ, Sweeny J, Kovacic JC, Shah S, Vijay P, Barman N, Kini A, Sharma S, Dangas GD, Mehran R. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J. 2018 Dec 7;39(46):4101-4108. doi: 10.1093/eurheartj/ehy633.</citation>
    <PMID>30358832</PMID>
  </results_reference>
  <results_reference>
    <citation>Ridker PM. Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin. Eur Heart J. 2016 Jun 7;37(22):1720-2. doi: 10.1093/eurheartj/ehw024. Epub 2016 Feb 22. Review.</citation>
    <PMID>26908943</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wuhan Union Hospital, China</investigator_affiliation>
    <investigator_full_name>Xiang Cheng</investigator_full_name>
    <investigator_title>Head of department of cardiology, Wuhan Union Hospital, China</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

